Fetma göder läkemedelsbolagen

episode

Börslunch not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

TNB Tech Minute: Nvidia Launches Largest-Ever U.S. Stock Buyback Program 3 min · 28 Sep 2026 · WSJ Tech News Briefing

Erdgas aus Deutschland – Umstrittene Bohrprojekte und die Suche nach Alternativen 28 min · 28 Sep 2026 · Das Wissen | SWR

Phone Tap: All Disabled Parking 10 min · 28 Sep 2026 · Brooke and Jeffrey

Do you guys know what a Chippewa is? | Local Hour 35 min · 28 Sep 2026 · The Dan Le Batard Show

Loser Line (9/28/26) 12 min · 28 Sep 2026 · Brooke and Jeffrey

"We went to support the players" 20 min · 28 Sep 2026 · Liveline

Report any issue

Source

Recorded18 Mar 2024

Publisheranchor.fm ↗

Handlerec:9306328

Show notes

Börslunch tar sig i detta avsnitt an läkemedelssektorn. Tillsammans med gästerna Ellinor Hult, Health Invest och Johan Unnerus, Redeye analyseras Novo Nordisk, Bioarctic, Xvivo Perfusion, Calliditas, Camurus och Fusion Pharmaceuticals.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related